EMA/430497/2011

# European Medicines Agency decision

P/180/2011

of 28 July 2011

on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread), (EMEA-000533-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

# European Medicines Agency decision

P/180/2011

of 28 July 2011

on the acceptance of a modification of an agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread), (EMEA-000533-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/18/2010 issued on 8 February 2010 and the decision P/51/2011 issued on 4 March 2011,

Having regard to the application submitted by Gilead Sciences International Limited on 4 April 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 17 June 2011, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

***Article 1***

Changes to the agreed paediatric investigation plan for tenofovir (disoproxil fumarate) (Viread), film-coated tablet, oral powder, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

***Article 2***

This decision is addressed to Gilead Sciences International Limited, Granta Park, Abington, CB21 6GT Cambridge, United Kingdom.

Done at London, 28 July 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Sign

EMA/PDCO/469888/2011

# Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000533-PIP01-08-M02

## Scope of the application

**Active substance(s):**

Tenofovir (disoproxil fumarate)

**Invented name:**

Viread

**Condition(s):**

Treatment of human immunodeficiency virus (HIV) disease resulting in other conditions

Treatment of chronic viral hepatitis B

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Film-coated tablet

Oral powder

**Route(s) of administration:**

Oral use

**Name/corporate name of the PIP applicant:**

Gilead Sciences International Limited

**Information about the authorised medicinal product:**

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Gilead Sciences International Limited submitted to the European Medicines Agency on 4 April 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/18/2010 issued on 8 February 2010, and the decision P/51/2011 issued on 4 March 2011

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 20 April 2011.

## Scope of the modification

Some of the agreed measures and timelines of the original Opinion have been modified.

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 17 June 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

# 1. Waiver

## *1.1. Condition: Treatment of human immunodeficiency virus (HIV) disease resulting in other conditions*

The waiver applies to:

- children from birth to less than 12 years of age;
- for tenofovir DF film-coated tablet for oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

## *1.2. Condition: Treatment of chronic viral hepatitis B*

The waiver applies to:

- children from birth to less than 12 years;
- for tenofovir DF film-coated tablet for oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

The waiver applies to:

- infants and toddlers from birth to less than 2 years;
- for tenofovir DF oral powder;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

# 2. Paediatric Investigation Plan

## *2.1. Condition: Treatment of human immunodeficiency virus (HIV) disease resulting in other conditions*

### 2.1.1. Indication(s) targeted by the PIP

In combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in antiretroviral treatment experienced paediatric patients

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

1) The paediatric population from 12 years to less than 18 years of age for the film-coated tablets for oral use

2) All subsets of the paediatric population from birth to less than 18 years of age for the oral powder

### 2.1.3. Studies

| Area | Number of studies | Description |
|---|---|---|
| Quality | | Not applicable. |
| Non-clinical | | Not applicable. |
| Clinical | 2 | Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents<br><br>Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Active Antiretroviral Therapy |
| | 1 | A safety and pharmacokinetic study of tenofovir DF oral powder in HIV-1 infected subjects < 2 years of age |

## *2.2. Condition: Treatment of chronic viral hepatitis B*

### 2.2.1. Indication(s) targeted by the PIP

For treatment of chronic hepatitis B in paediatric patients from 2 years of age with compensated liver disease

### 2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

1) The paediatric population from 12 years to less than 18 years of age for the film-coated tablets for oral use

2) All subsets of the paediatric population from 2 years to less than 18 years of age for the oral powder

### 2.2.3. Studies

| Area | Number of studies | Description |
|---|---|---|
| **Quality** | | Not applicable. |
| **Non-clinical** | | Not applicable. |
| **Clinical** | 1 ongoing | A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection |
| | 1 planned | A safety and efficacy or pharmacokinetic study of tenofovir DF in children aged 2 to < 12 years with chronic HBV infection |

# 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Measures to address long term follow-up of potential safety issues or efficacy in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By September 2017 |
| Deferral for some or all studies contained in the paediatric investigation plan: | Yes |

# Annex II

# Information about the authorised medicinal product

**Condition(s) and authorised indication(s):**

1. Treatment of HIV disease

   Authorised indications:

Viread is indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected adults over 18 years of age.

2. Treatment of chronic viral hepatitis B

   Authorised indication:

   Viread is indicated for the treatment of chronic Hepatitis B in adults with compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

   Viread is indicated for the treatment of chronic Hepatitis B in adults with decompensated liver disease.

| **EU Number** | **Invented Name** | **Strength** | **Pharmaceutical form** | **Route of administration** | **Packaging** | **Content (concentration)** | **Package size** |
|---|---|---|---|---|---|---|---|
| EU/1/01/200/001 | Viread | 245 mg | Film-coated tablet | Oral use | Bottle (HDPE) | | 30 tablets |
| EU/1/01/200/002 | Viread | 245 mg | Film-coated tablet | Oral use | Bottle (HDPE) | | 3 x 30 tablets |